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Abstract
Background: To study the link between the dosage of several antipsychotics and the prescription
of antiparkinsonians in an observational study.
Methods: In the context of a national naturalistic prospective observational study, a database
containing all the prescriptions from 100 French psychiatrists during the year 2002 was analysed.
The inclusion criteria were a diagnosis of schizophrenia or schizoaffective disorder and age over
18. The mean dosage of antipsychotics with and without antiparkinsonians was compared. Since
there were multiple prescriptions for a given subject, generalised mixed linear models were also
used to study the link between antiparkinsonian prescription and antipsychotic dosage.
Results: antiparkinsonians were prescribed to 32,9% of the patients. Two groups of antipsychotics
were observed relating to differences in dosage when an antiparkinsonian was co prescribed or not
: a first group, where the mean dosage was higher with antiparkinsonians (risperidone, amisulpride
and haloperidol) and a second group (clozapine, olanzapine), in which antiparkinsonian co
prescription was not related to the dosage of antipsychotics.
Conclusion: As a conclusion, it can be said that it is important to consider the dosage and the
type of antipsychotic in the treatment of patients suffering of schizophrenia, because neurological
side effects are frequent and can impair quality of life. Moreover the prescription of
antiparkinsonians can lead to different side effects such anticholinergic effects.
Background
Over the last decade, a new generation of antipsychotics
has emerged. In certain randomised trials, these new
antipsychotics has been proved to cause less neurological
side effects than traditional antipsychotics[1-4]. Neverthe-
less, recent meta-analyse tend to show that only certain
classes of atypical antipsychotics (olanzapine and clozap-
ine) lead to fewer adverse neurological events[5-7]. These
meta-analyses point out that the dosage of antipsychotics
is decisive for the occure of adverse neurological events.
Because randomised trials study antipsychotics for one or
several different dosages, these studies have limitations in
the analysis of the link between neurological adverse
events and antipsychotic dosage [1].
Observational studies make it possible to study antipsy-
chotic dosage as it is prescribed in ordinary practice. In
addition, antiparkinsonians are prescribed for neurologi-
cal side effects in schizophrenia and the frequency of their
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prescription reflects the frequency of neurological side
effects[8].
The aim of this analysis is to study the link between antip-
sychotic dosage and the prescription of antiparkinsonians
in an observational study.
Method
Data sources
Data for the study is derived from the Thales company
database. This company has developed an exhaustive
computerized medical file system used by a panel of ran-
domised French psychiatrists. For each consultation, treat-
ment and diagnosis were entered directly by the
psychiatrist. Diagnoses were made in the context of day to
day practice, without the use of standardized interviews.
The software provided printouts of prescriptions and
recorded data in a central data base. The practitioners were
not paid for their participation.
Sample
The psychiatrists in the panel were private practitioners.
They were chosen at random with stratification for area of
practice, gender and age. Other characteristics like salary,
the kind of practice (private only, private and public prac-
tice) were compared with the French national social secu-
rity register. Regarding all these characteristics, the panel
of 100 psychiatrists was representative of the French pop-
ulation of private practitioners.
All the subjects included were outpatients. Inclusion crite-
ria were as follow: patients over 18 who consulted any
psychiatrist on the panel at least once in the period from
02/01/01 to 02/12/31 and who had at least once received
a diagnosis of schizophrenia or schizoaffective disorder,
on the DSM-IV criteria[9].
The variables retained in our analysis were socio-demo-
graphic data (age, gender), diagnosis (schizophrenia,
schizoaffective disorder, other associated diagnosis) and
medication. Any medications of potential interests for the
object of study was retained (olanzapine, risperidone,
clozapine, amisulpride, haloperidol).
Olanzapine, risperidone, clozapine, amisulpride were
considered as atypical antipsychotics whereas haloperidol
was considered as a typical antipsychotic.
Analysis
In a first step, the frequency of prescription was deter-
mined for each antipsychotic and antiparkinsonian. The
mean dosage of antipsychotics with and without antipar-
kinsonians was also calculated.
In a second step, the frequency of antiparkinsonian co
prescriptions for different dosages of several different
antipsychotics, converted into chlorpromazine dosage
equivalent, was studied.
Since there were multiple prescriptions for given subject,
generalised linear mixed models were also used. Further-
more, different antipsychotics could be co prescribed.
Thus, the dosage of antipsychotics studied as variables of
interest and the co prescription of antipsychotics other
than haloperidol, olanzapine, risperidone, amisulpride
and clozapine were entered into the model as confound-
ing variables, as well as age and gender. The prescription
of antiparkinsonians was considered as the dependant
variable [10-13].
For statistical analyses, SAS 8.2 software was used, proc
gen mod was used for the mixed models[14].
Results
During 2002, 2523 patients consulted a psychiatrist from
the panel of 100 psychiatrists at least once. 922 subjects
suffering from schizophrenia or shizo-affective disorder
were included. 85,6% received a diagnosis of schizophre-
nia at least once in 2002, 31,9% a diagnosis of schizo-
affective disorder, and 11,8% an associated diagnosis of
affective disorders. 28,9% of patients had at least two dif-
ferent diagnoses. All subjects included were prescribed
medication at least once.
Demographic characteristics
There were no missing data for the variable gender and 2
missing data for age. Mean age was 39.7 (min = 18, max =
90, sd = 12.0). Men were younger than women (38,2 vs
41,8 ; p < 0,01) and represented 57.9% of the sample pop-
ulation.
In order to check the representative ness of the sample of
patients, demographic data were compared with referen-
tial data from another French naturalistic study [15].
There was no significant difference considering the sex
ratio (57,9% vs 60,9% ; p = 0,1) and no significant differ-
ence between mean age (39,7 vs 39,2; p = 0,2).
Prescriptions
On average, a patient received 6.0 prescriptions in the year
2002 (sd = 2,2). The mean number of psychotropic med-
ications per prescription was 2.6 (sd = 1,1). Antiparkinso-
nians were prescribed to about one third of the patients
(table 1).
13,6% of olanzapine prescriptions are associated with
antiparkinsonians. Haloperidol is more often co pre-
scribed with antiparkinsonians (38,2% of the prescrip-
tions of haloperidol) than atypical antipsychotics (17,3%Clinical Practice and Epidemiology in Mental Health 2007, 3:14 http://www.cpementalhealth.com/content/3/1/14
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for risperidone, 35,2% for amisulpride). For clozapine,
only three cases of antiparkinsonian co prescriptions are
recorded.
Table 2 indicates the characteristics of dosage for the dif-
ferent antipsychotics.
Comparison of dosage between antipsychotics prescribed 
with and without antiparkinsonians (table 3)
Two groups of antipsychotics were observed: a first group
(risperidone, amisulpride and haloperidol) where mean
dosage was higher with antiparkinsonians, and a second
group, in which the dosage of antipsychotics (clozapine,
olanzapine) did not differ with or without antiparkinso-
nians (table 3).
Percentage of antiparkinsonian co prescription in relation 
to antipsychotic dosage
Figure 1 indicates the evolution of the percentage of
antiparkinsonian co prescriptions in relation to antipsy-
chotic dosage. A stable percentage of antiparkinsonian co
prescriptions for the different doses of olanzapine was
observed. Concerning risperidone and amisulpride, the
increase in antiparkinsonian co prescriptions is propor-
tional to the dosage of risperidone.
Factor influencing antiparkinsonian prescription 
(generalized mixed linear models)
The other antipsychotics co prescribed with each of antip-
sychotics studied (olanzapine, risperidone, clozapine,
amisulpride and haloperidol) did not appear to be signif-
icant confounding variables.
The results of the comparison of means are confirmed.
Antiparkinsonian co prescriptions increase with the dos-
age for amisulpride, risperidone and haloperidol whereas
they are independent of the dosage for olanzapine and
clozapine.
Discussion
This naturalistic study is likely to be more representative
of day to day practice than randomised trials, in terms of
selection of population, number of prescriptions studied,
dosage and time of follow up[8]. This kind of study has
nevertheless certain limitations, among which the lack of
randomisation.
Despite the emergence of a new generation of antipsy-
chotics, the co-prescription of antiparkinsonians is still
Table 2: Mean dosage of antipsychotics according to co-prescription of antiparkinsonians (univariate analysis)
All 
prescriptio
ns
(n = 5712)
Prescriptions with no 
antiparkinsonian
(n = 4148)
Prescriptions with 
antiparkinsonian
(n = 1564)
Comparisons of means
n Mean 
dosage mg 
(chlorproma
zine 
equivalents) 
[CI95%]
Range of 
dosage 
Median 
(min-max)
n Mean 
dosage
n Mean 
dosage
tp
olanzapine 1278 10,9 (218)
[10,6–11,3]
10 (5–30) 1104 10,7 174 11,3 0,84 0,4
risperidone 713 3,5 (175)
[3,3–3,7]
4 (0,5–12) 590 3,2 123 5,3 7,8 <0,0001
amisulpride 967 365 (243)
[346–382]
200 (50–
1200)
627 298 340 468,2 10,1 <0,0001
clozapine 44 90,6 (181)
[75,8–
115,5]
75 (12,5–
450)
41 89,9 3 100,0 0,8 0,05 
haloperidol 452 6,6 (330)
[6,1–7,2]
5 (0,1–30) 173 3,9 279 8,4 68,9 <0,0001
Table 1: Frequency of antipsychotic and antiparkinsonian 
prescriptions
% of patients who 
have received the 
treatment at least 
once in 2002
(n = 922)
% of prescriptions 
where the treatement is 
prescribed
(n = 5712)
Treatment % n % n
olanzapine 28.6 264 22.4 1278
risperidone 19.1 176 12.5 713
amisulpride 20.5 189 16.9 967
clozapine 0.8 7 0.8 44
haloperidol* 16.6 153 8.1 462
antiparkinsonians 32.9 303 27.3 1564
* oral or depotClinical Practice and Epidemiology in Mental Health 2007, 3:14 http://www.cpementalhealth.com/content/3/1/14
Page 4 of 5
(page number not for citation purposes)
high (32,9%). This probably means that neurological side
effects are a real problem for about one third of the
patients treated with antipsychotics.
This analysis underlines the importance of the dosage of
antipsychotics for the occurrence of neurological side
effects. The patients under higher doses of amisulpride or
risperidone (over 300 mg in chlorpromazine dose equiv-
alent) are as likely to need antiparkinsonians as those
under a traditional neuroleptic as haloperidol. Consider-
ing dosage of olanzapine and clozapine, the occurence of
neurological side effects seems to be stable.
Another important point is that it is known that the com-
bination of several antipsychotics increase the frequency
of antiparkinsonian prescription [18-20] but the presence
of another antipsychotic does not appear decisive in this
study for the link between dosage of antipsychotics and
prescription of antiparkinsonians.
As a conclusion, it can be said that the difference between
atypical and typical antipsychotics is confirmed here in
terms of the percentage of antiparkinsonian co prescrip-
tions and hence neurological side effects. However, these
differences depend on the dosage of antipsychotics.
This point is important in considering the treatment of
patients suffering of schizophrenia because neurological
side effects impair quality of life. It is also important
because the prescription of antiparkinsonians can lead to
different adverse effects such anticholinergic effects.
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